Your browser is no longer supported. Please, upgrade your browser.
Settings
LLY Eli Lilly and Company daily Stock Chart
LLY [NYSE]
Eli Lilly and Company
IndexS&P 500 P/E37.30 EPS (ttm)2.31 Insider Own11.20% Shs Outstand1.10B Perf Week-0.12%
Market Cap94.62B Forward P/E18.69 EPS next Y4.60 Insider Trans-1.18% Shs Float1.10B Perf Month4.29%
Income2.45B PEG3.27 EPS next Q1.03 Inst Own77.80% Short Float1.13% Perf Quarter2.17%
Sales22.00B P/S4.30 EPS this Y14.10% Inst Trans-0.17% Short Ratio3.52 Perf Half Y6.39%
Book/sh13.37 P/B6.44 EPS next Y10.57% ROA6.30% Target Price90.48 Perf Year9.59%
Cash/sh4.94 P/C17.41 EPS next 5Y11.41% ROE17.00% 52W Range64.18 - 89.09 Perf YTD17.01%
Dividend2.08 P/FCF26.28 EPS past 5Y-8.00% ROI11.60% 52W High-3.40% Beta0.35
Dividend %2.42% Quick Ratio1.00 Sales past 5Y-2.70% Gross Margin73.90% 52W Low34.09% ATR1.16
Employees41975 Current Ratio1.40 Sales Q/Q7.80% Oper. Margin14.20% RSI (14)62.87 Volatility1.12% 1.35%
OptionableYes Debt/Eq0.87 EPS Q/Q35.20% Profit Margin11.10% Rel Volume1.03 Prev Close85.95
ShortableYes LT Debt/Eq0.70 EarningsOct 24 BMO Payout89.00% Avg Volume3.52M Price86.06
Recom2.30 SMA200.79% SMA504.26% SMA2005.60% Volume3,612,013 Change0.13%
Oct-10-17Downgrade Credit Suisse Outperform → Neutral
Jul-26-17Downgrade Leerink Partners Outperform → Mkt Perform
Apr-27-17Downgrade Argus Buy → Hold
Apr-17-17Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-07-17Reiterated Barclays Overweight $85 → $90
Mar-20-17Reiterated UBS Neutral $70 → $85
Dec-16-16Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-27-16Upgrade Goldman Neutral → Buy
Sep-08-16Upgrade JP Morgan Neutral → Overweight
May-02-16Reiterated Leerink Partners Outperform $96 → $101
Apr-06-16Initiated Societe Generale Hold $78
Dec-28-15Reiterated Leerink Partners Outperform $93 → $95
Dec-07-15Upgrade Deutsche Bank Hold → Buy $85 → $99
Dec-01-15Upgrade Barclays Equal Weight → Overweight $75 → $95
Nov-12-15Reiterated Leerink Partners Outperform $90 → $93
Oct-09-15Upgrade Credit Suisse Neutral → Outperform
Sep-21-15Reiterated JP Morgan Neutral $83 → $90
Sep-18-15Reiterated Jefferies Buy $105 → $115
Sep-18-15Reiterated BofA/Merrill Buy $101 → $108
Aug-27-15Initiated Berenberg Buy
Oct-17-17 06:27PM  Trump favors ex-pharma executive Azar for health secretary -Politico Reuters
05:00PM  This hot trade is about to get even hotter: Trader CNBC Videos
10:36AM  How Eli Lillys Taltz Is Positioned after 1H17 Market Realist
09:07AM  Positioning Eli Lillys Cardiovascular Franchise Positioned after 1H17 Market Realist
Oct-16-17 02:45PM  Lilly Declares Fourth-Quarter 2017 Dividend PR Newswire
10:58AM  The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad Forbes
10:38AM  This Could Be Eli Lillys Long-Term Growth Driver Market Realist
09:07AM  Inside Eli Lillys Oncology Portfolio: Key Updates Market Realist
07:38AM  Gauging Eli Lillys Position with Cyramza after 1H17 Market Realist
06:45AM  Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis PR Newswire
Oct-13-17 04:14PM  5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings Zacks
03:06PM  This Could Boost Eli Lillys Revenue Growth in 2018 Market Realist
01:35PM  How Eli Lilly Is Positioned after 1H17 Market Realist
11:42AM  Behind Eli Lillys October Analyst Recommendations Market Realist
11:18AM  Cancer Space Update: Lung & Breast Cancer Studies in Focus Zacks
09:02AM  Lilly's Verzenio Gets Priority Review in First-Line Setting Zacks
08:06AM  Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback Zacks
Oct-12-17 07:40AM  Featured Company News Eli Lilly Announces That Verzenio Failed To Meet Primary Endpoint of Overall Survival in Phase-3 JUNIPER Study ACCESSWIRE
06:45AM  FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio (abemaciclib) as Initial Treatment of Advanced Breast Cancer PR Newswire
Oct-11-17 10:40AM  Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study Zacks
Oct-10-17 04:03PM  Closing Bell: LIVE MARKETS BLOG TheStreet.com
02:55PM  Monday Night Football Posts Lowest Ratings of the Season: LIVE MARKETS BLOG TheStreet.com
01:05PM  Lilly's breast cancer drug fails to help lung patients Reuters
12:45PM  Trian to Contest P&G Vote: LIVE MARKETS BLOG TheStreet.com
12:45PM  NFL Caves to Trump, Considers Regulating Anthem Protest: LIVE MARKETS BLOG TheStreet.com
12:32PM  P&G Will Listen to Peltz as Company's Largest Shareholder :LIVE MARKETS BLOG TheStreet.com
10:50AM  Retirees and Legacy Investors Are Unhappy With P&G Peltz Says :LIVE MARKETS BLOG TheStreet.com
10:33AM  7 Catalysts For Eli Lilly Over The Next Year Benzinga
10:20AM  Eli Lilly Loses Some Luster Barrons.com
10:01AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings Zacks
09:57AM  P&G Vote May Be Too Close to Call Today, Peltz Says: LIVE MARKETS BLOG TheStreet.com
09:35AM  Opening Bell: LIVE MARKETS BLOG TheStreet.com
08:41AM  Eli Lilly's stock sinks after disappointing results from late-stage trial of cancer treatment MarketWatch
08:17AM  Earnings Calendar: LIVE MARKETS BLOG TheStreet.com
08:06AM  Late Stage Cancer Drug Failure Sinks Eli Lilly: LIVE MARKETS BLOG TheStreet.com
06:58AM  Lilly's lung cancer drug fails late-stage study Reuters
06:45AM  Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer PR Newswire
Oct-09-17 10:13AM  Cancer Space Last Week Update: Pipeline Expansion in Focus Zacks
Oct-08-17 09:00AM  It has been a brutal year in the search for a treatment for Alzheimers heres where researchers are looking now Business Insider
Oct-06-17 06:27PM  FDA: Drug shortages possible due to Puerto Rico power outage Associated Press
01:00PM  Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio (abemaciclib) Plus NSAI in Advanced Breast Cancer PR Newswire
09:37AM  No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock InvestorPlace
09:07AM  Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal Zacks
08:50AM  Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute Zacks
Oct-05-17 04:43PM  Lilly wins Alimta patent dispute in US Reuters
04:36PM  Eli Lilly defeats challenge to Alimta cancer drug patent Reuters
04:13PM  U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent PR Newswire
03:48PM  Additional Delivery of Insulin Ready for Distribution in Puerto Rico PR Newswire
10:38AM  Changes in GlaxoSmithKlines Valuation Market Realist
07:37AM  Changes in Eli Lillys Valuation Market Realist
Oct-04-17 10:38AM  Quarterly Performance of Eli Lillys Elanco Market Realist
09:07AM  Quarterly Performance of Eli Lillys Neuroscience Products Market Realist
09:00AM  Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes PR Newswire
07:40AM  Quarterly Performance of Eli Lillys Cardiovascular Products Market Realist
Oct-03-17 10:59AM  Johnson & Johnson Files sNDA for Label Expansion of Invokana Zacks
10:40AM  Quarterly Performance of Eli Lillys Endocrine Franchise Market Realist
09:08AM  Quarterly Performance of Eli Lillys Oncology Products Market Realist
07:42AM  Quarterly Performance of Eli Lillys New Products Market Realist
Oct-02-17 06:19PM  Lilly (LLY) Makes Leadership Changes to Executive Positions Zacks
03:06PM  Quarterly Performance of Eli Lillys Business Segments Market Realist
01:36PM  Eli Lillys Quarterly Revenues and Estimates Market Realist
11:43AM  Eli Lillys Recent Developments after 2Q17 Market Realist
10:00AM  Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement PR Newswire
07:40AM  Corporate News Blog - Eli Lilly Declares New Appointments for Senior Leadership in Finance, Research & Development, and Manufacturing ACCESSWIRE
07:33AM  These Are the Top 5 Stocks the Smart Money Is Selling Motley Fool
Sep-30-17 12:31AM  [$$] Eli Lilly Names Joshua Smiley CFO The Wall Street Journal
Sep-29-17 10:40AM  Must-Know Changes to Bristol-Myers Squibbs Valuation Market Realist
10:26AM  Lilly names new CFO, replaces head of R&D in management shakeup Reuters
08:14AM  [$$] Eli Lilly Names Joshua Smiley CFO The Wall Street Journal
06:45AM  Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing PR Newswire
Sep-28-17 06:20PM  FDA approves Lilly pill for common advanced breast cancer Associated Press
04:41PM  Eli Lilly wins U.S. approval for breast cancer drug Reuters
08:05AM  Elanco Celebrates 10 Years of Volunteerism During Global Day of Service PR Newswire
Sep-27-17 10:17AM  Pharmaceuticals: A Solid End To 2017 Barrons.com
07:37AM  What Happened to Allergans Valuation after 2Q17? Market Realist
07:01AM  Bullish Pattern Showing for Eli Lilly: Cramer's 'Off the Charts' TheStreet.com
Sep-26-17 07:13PM  Cramer's charts diagnose a potential breakout for shares ... CNBC Videos
07:07PM  Cramer charts: Potential breakout for Eli Lilly CNBC Videos
07:05PM  Cramer Remix: Why Apple is the Muhammad Ali of stocks CNBC Videos
07:00PM  Cramer Remix: Why Apple is the Muhammad Ali of stocks CNBC
01:27PM  Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why Zacks
07:12AM  J&J's Arthritis Candidate Sirukumab Denied FDA Approval Zacks
Sep-25-17 08:30AM  Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death PR Newswire
08:00AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
Sep-22-17 01:08PM  AstraZeneca Stock Upgraded: What You Need to Know Motley Fool
08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
Sep-21-17 08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
Sep-15-17 11:34PM  [$$] 4 Buys in a Watchful Market Barrons.com
01:45PM  Eli Lilly Still Looking for Lower Prices TheStreet.com
01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
09:51AM  Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study Zacks
09:07AM  Why New Generic Products Could Boost TEVAs Revenue Growth Market Realist
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
Sep-14-17 03:17PM  Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017 Capital Cube
02:49PM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
12:20PM  US stocks are mixed as energy companies rise, retailers dip Associated Press
11:35AM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
09:00AM  Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
03:30AM  Astra's Farxiga results may open up type 1 diabetes opportunity Reuters
Sep-13-17 03:44PM  Is Lilly Headed for the Valley? TheStreet.com
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LILLY ENDOWMENT INC10% OwnerOct 04Sale86.81205,00017,795,025123,275,804Oct 05 02:56 PM
LILLY ENDOWMENT INC10% OwnerSep 29Sale85.14195,00016,602,601123,480,804Oct 02 03:39 PM
LILLY ENDOWMENT INC10% OwnerSep 15Sale82.53190,00015,679,772123,675,804Sep 18 03:42 PM
LILLY ENDOWMENT INC10% OwnerAug 31Sale81.06180,00014,590,080123,865,804Sep 01 01:45 PM
LILLY ENDOWMENT INC10% OwnerJul 31Sale83.09220,00018,279,478124,045,804Aug 01 10:55 AM
LILLY ENDOWMENT INC10% OwnerJun 22Sale84.43210,00017,730,720124,265,804Jun 23 10:16 AM
LILLY ENDOWMENT INC10% OwnerJun 20Sale83.05215,00017,855,363124,475,804Jun 21 11:24 AM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMJun 12Sale80.781,900153,48214,041Jun 13 04:10 PM
Harrington Michael JSenior VP and General CounselJun 09Sale79.9722,8331,825,95562,056Jun 09 04:15 PM
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSAMay 04Sale82.7625,0002,069,000114,217May 08 03:44 PM
LILLY ENDOWMENT INC10% OwnerMar 30Sale84.67210,00017,781,540124,690,804Mar 31 11:11 AM
LILLY ENDOWMENT INC10% OwnerFeb 17Sale80.27230,00018,462,790125,125,804Feb 21 03:45 PM
Zulueta Alfonso GSVP& Pres., Emerging MarketsFeb 06Sale77.6615,0001,164,90045,583Feb 08 10:02 AM
Rice Derica WEVP-Global Services and CFOFeb 03Sale77.473,892301,51338,292Feb 03 05:20 PM
Rice Derica WEVP-Global Services and CFOFeb 02Sale76.977,270559,57242,184Feb 03 05:20 PM
Zakrowski Donald AChief Accounting OfficerFeb 02Sale77.522,000155,040886Feb 03 03:22 PM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMFeb 01Option Exercise0.003,073017,361Feb 03 03:24 PM
Zulueta Alfonso GSVP& Pres., Emerging MarketsFeb 01Option Exercise0.006,659063,710Feb 03 03:20 PM
Walsh Fionnuala MSVP, Global QualityFeb 01Option Exercise0.004,610069,309Feb 03 03:18 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthFeb 01Option Exercise0.0010,2440141,753Feb 03 03:16 PM
Ricks David APresident & CEOFeb 01Option Exercise0.0010,2440109,400Feb 03 03:13 PM
Peterson Barton RSr. VP, Corp. Affairs & Comm.Feb 01Option Exercise0.005,6340110,958Feb 03 03:11 PM
Mahony SusanSVP & Pres., Lilly OncologyFeb 01Option Exercise0.009,732096,040Feb 03 03:08 PM
Lundberg Jan MEVP,Science&Tech and Pres. LRLFeb 01Option Exercise0.0015,3660162,368Feb 03 03:04 PM
LECHLEITER JOHN CDirectorFeb 01Option Exercise0.0046,0970855,987Feb 03 03:01 PM
Harrington Michael JSenior VP and General CounselFeb 01Option Exercise0.009,732089,432Feb 03 02:58 PM
Fry Stephen FSVP, HR & DiversityFeb 01Option Exercise0.007,683082,552Feb 03 02:53 PM
Crowe Maria APresident, Mfg. OperationsFeb 01Option Exercise0.008,1950117,313Feb 03 02:41 PM
Conterno Enrique ASr. VP & Pres., Lilly DiabetesFeb 01Option Exercise0.0010,2440144,027Feb 03 02:35 PM
Rice Derica WEVP-Global Services and CFOFeb 01Option Exercise0.0019,463058,443Feb 03 05:20 PM
LILLY ENDOWMENT INC10% OwnerFeb 01Sale77.35220,00017,016,840125,355,804Feb 02 03:38 PM
HOOVER R DAVIDDirectorDec 16Buy71.8550035,9251,500Dec 19 02:15 PM
TAI JACKSON PDirectorDec 16Buy72.641,37599,88048,815Dec 19 02:45 PM
LILLY ENDOWMENT INC10% OwnerDec 16Sale72.59200,00014,518,477125,575,804Dec 19 05:02 PM
Zakrowski Donald AChief Accounting OfficerDec 16Sale72.131,00072,130300Dec 19 02:48 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 16Sale72.681,14983,50911,479Dec 19 02:40 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 16Sale72.6519,0931,387,10667,802Dec 19 02:40 PM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMDec 16Sale82.232,093172,1078,169Dec 19 02:10 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 01Option Exercise0.004,584014,117Dec 05 02:29 PM